High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4561-4567

  Xu, Xiulong ^a   Quiros, Roderick M ^a   Gattuso, Paolo ^a   Ain, Kenneth B ^b,c   Prinz, Richard A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; ONCOPROTEIN; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GOITER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; ONCOGENE BRAF; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; EXONS; FEMALE; GENE ORDER; HUMANS; MALE; MUTATION; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; SEX FACTORS; THYROID NEOPLASMS;

EID: 0041589377     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Gimm, O. Thyroid cancer. Cancer Lett., 163: 143-156, 2001.
2. Saavedra, H. I., Knauf, J. A., Shirokawa, J. M., Wang, J., Ouyang, B., Elisei, R., Stambrook, P. J., and Fagin, J. A. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene, 19: 3948-3954, 2000.
3. Lyons, J., Landis, C. A., Harsh, G., Vallar, L., Grunewald, K., Feichtinger, H., Duh, Q. Y., Clark, O. H., Kawasaki, E., Bourne, H. R., et al. Two G protein oncogenes in human endocrine tumors. Science (Wash. DC), 249: 655-659, 1990.
4. O'Sullivan, C., Barton, C. M., Staddon, S. L., Brown, C. L., and Lemoine, N. R. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol. Carcinog., 4: 345-349, 1991.
5. Suarez, H. G., du Villard, J. A., Caillou, B., Schlumberger, M., Parmentier, C., and Monier, R. gsp mutations in human thyroid tumours. Oncogene, 6: 677-679, 1991.
6. Esapa, C. T., Johnson, S. J., Kendall-Taylor, P., Lennard, T. W., and Harris, P. E. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol. (Oxf), 50: 529-535, 1999.
7. Krohn, K., Reske, A., Ackermann, F., Muller, A., and Paschke, R. Ras mutations are rare in solitary cold and toxic thyroid nodules, Clin. Endocrinol. (Oxf), 55: 241-248, 2001.
8. Lemoine, N. R., Mayall, E. S., Williams, E. D., Thurston, V., and Wynford-Thomas, D. Agent-specific ras oncogene activation in rat thyroid tumours. Oncogene, 3: 541-544, 1988.
9. Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Farr, C. J., Hughes, D., Padua, R. A., Thurston, V., Williams, E. D., and Wynford-Thomas, D. Activated ras oncogenes in human thyroid cancers. Cancer Res., 48: 4459-4463, 1988.
10. Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Williams, E. D., Goyns, M., Stringer, B., and Wynford-Thomas, D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene, 4: 159-164, 1989.
11. Namba, H., Gutman, R. A., Matsuo, K., Alvarez, A., and Fagin, J. A. H-ras protooncogene mutations in human thyroid neoplasms. J. Clin. Endocrinol. Metab., 71: 223-229, 1990.
12. Park, K. Y., Koh, J. M., Kim, Y. I., Park, H. J., Gong, G., Hong, S. J., and Ahn, I. M. Prevalences of Gs α, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin. Endocrinol. (Oxf), 49: 317-323, 1998.
13. Wright, P. A., Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Hughes, D., Williams, E. D., and Wynford-Thomas, D. Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br. J. Cancer, 60: 576-577, 1989.
14. Wright, P. A., Williams, E. D., Lemoine, N. R., and Wynford-Thomas, D. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene, 6: 471-473, 1991.
15. Shi, Y. F., Zou, M. J., Schmidt, H., Juhasz, F., Stensky, V., Robb, D., and Farid, N. R. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res., 51: 2690-2693, 1991.
16. Suarez, H. G., Du Villard, J. A., Caillou, B., Schlumberger, M., Tubiana, M., Parmentier, C., and Monier, R. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene, 2: 403-406, 1988.
17. Suarez, H. G., du Villard, J. A., Severino, M., Caillou, B., Schlumberger, M., Tubiana, M., Parmentier, C., and Monier, R. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene, 5: 565-570, 1990.
18. Said, S., Schlumberger, M., and Suarez, H. G. Oncogenes and anti-oncogenes in human epithelial thyroid tumors. J. Endocrinol. Investig., 17: 371-379, 1994.
19. Klugbauer, S., and Rabes, H. M. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene, 18: 4388-4393, 1999.
20. Beimfohr, C., Klugbauer, S., Demidchik, E. P., Lengfelder, E., and Rabes, H. M. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int. J. Cancer, 80: 842-847, 1999.
21. Tallini, G., and Asa, S. L. RET oncogene activation in papillary thyroid carcinoma, Adv. Anat. Pathol., 8: 345-354, 2001.
22. Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Porta, G., Fusco, A., and Vecchio, G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 60: 557-563, 1990.
23. Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bongarzone, I., Della Porta, G., Berger, N., et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Investig., 89: 1517-1522, 1992.
24. Santoro, M., Melillo, R. M., Grieco, M., Berlingieri, M. T., Vecchio, G., and Fusco, A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ., 4: 77-84, 1993.
25. Dobashi, Y., Sakamoto, A., Sugimura, H., Memyei, M., Mori, M., Oyama, T., and Machinami, R. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am. J. Surg. Pathol., 17: 375-381, 1993.
26. Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., and Koeffler, H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Investig., 91: 179-184, 1993.
27. Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, Y., Dohi, K., Nakamura, N., and Akiyama, M. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn. J. Cancer Res., 84: 526-531, 1993.
28. Thiagalingam, A., De Bustros, A., Borges, M., Jasti, R., Compton, D., Diamond, L., Mabry, M., Ball, D. W., Baylin, S. B., and Nelkin, B. D. RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas. Mol. Cell. Biol., 16: 5335-5345, 1996.
29. Elisei, R., Shiohara, M., Koeffler, H. P., and Fagin, J. A. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer (Phila.), 83: 2185-2193, 1998.
30. Baldassarre, G., Belletti, B., Bruni, P., Boccia, A., Trapasso, F., Pentimalli, F., Barone, M. V., Chiappetta, G., Vento, M. T., Spiezia, S., Fusco, A., and Viglietto, G. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Investig., 104: 865-874, 1999.
31. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
32. Fagin, J. A. Molecular genetics of human thyroid neoplasms. Annu. Rev. Med., 45: 45-52, 1994.
33. Ain, K., Taylor, K., Rofiq, S., and Venkataraman, G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab., 82: 1857-1862, 1997.
34. Hasegawa, Y., Takeda, S., Ichii, S., Koizumi, K., Maruyama, M., Fujii, A., Ohta, H., Nakajima, T., Okuda, M., Baba, S., et al. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene, 10: 1441-1445, 1995.
35. Linard, B., Bezieau, S., Benlalam, H., Labarriere, N., Guilloux, Y., Diez, E., and Jotereau, F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Immunol., 168: 4802-4808, 2002.
36. Bongarzone, I., Vigneri, P., Mariani, L., Collini, P., Pilotti, S., and Pierotti, M. A. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin. Cancer Res., 4: 223-228, 1998.
37. Sugg, S. L., Ezzat, S., Rosen, I. B., Freeman, J. L., and Asa, S. L. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab., 83: 4116-4122, 1998.
38. Tallini, G., Santoro, M., Helie, M., Carlomagno, F., Salvatore, G., Chiapetta, G., Carcangiu, M. L., and Fusco, A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res., 4: 287-294, 1998.
39. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, Cancer Res., 63: 1454-1457, 2003.
40. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond.). 418: 934, 2002.
41. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
42. Pollock, P. M., and Meltzer, P. S. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell, 2: 5-7, 2002.
43. Yuen, S. T., Davies, H., Chan, T. L., Ho, J. W., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S., Futreal, P. A., Stratton, M. R., Wooster, R., and Leung, S. Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res., 62: 6451-6455, 2002.
44. Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., and Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res., 62: 7001-7003, 2002.
45. Namba, H., Rubin, S. A., and Fagin, J. A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol., 4: 1474-1479, 1990.
46. Suarez, H. G. Genetic alterations in human epithelial thyroid tumours. Clin. Endocrinol. (Oxf.), 48: 531-546, 1998.
47. Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H., and Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res., 57: 1690-1694, 1997.
48. Bounacer, A., Wicker, R., Caillou, B., Cailleux, A. F., Sarasin, A., Schlumberger, M., and Suarez, H. G. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene, 15: 1263-1273, 1997.
49. Russo, D., Arturi, F., Schlumberger, M., Caillou, B., Monier, R., Filetti, S., and Suarez, H. G. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene, 11: 1907-1911, 1995.
50. Sugg, S. L., Ezzat, S., Zheng, L., Freeman, J. L., Rosen, I. B., and Asa, S. L. Oncogene profile of papillary thyroid carcinoma. Surgery (St. Louis), 125: 46-52, 1999.
51. Erhardt, P., Schremser, E. J., and Cooper, G. M. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol., 19: 5308-5315, 1999.
52. Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux, C., Eychene, A., Ortonne, J. P., and Ballotti, R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J., 19: 2900-2910, 2000.
53. Halaban, R. The regulation of normal melanocyte proliferation. Pigm. Cell Res., 13: 4-14, 2000.
54. Kimura, T., Van Keymeulen, A., Golstein, J., Fusco, A., Dumont, J. E., and Roger, P. P. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr. Rev., 22: 631-656, 2001.
55. Medina, D. L., and Santisteban, P. Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. Eur. J. Endocrinol., 143: 161-178, 2000.
56. Pomerance, M., Abdullah, H. B., Kamerji, S., Correze, C., and Blondeau, J. P. Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade. Involvement of protein kinase A, rac1, and reactive oxygen species. J. Biol. Chem., 275: 40539-46, 2000.
57. Tsygankova, O. M., Saavedra, A., Rebhun, J. F., Quilliam, L. A., and Meinkoth, J. L. Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol. Cell. Biol., 21: 1921-1929, 2001.
58. Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., and Tallini, G. β-Catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol., 158: 987-996, 2001.